Systemic immunosuppression in ocular surface stem cell transplantation: Results of a 10-year experience

Cornea

Volumn 31, Issue 6, 2012, Pages 655-661

  Holland, Edward J ^a,b   Mogilishetty, Gautham ^b   Skeens, Heather M ^c   Hair, David B ^d   Neff, Kristiana D ^e   Biber, Joseph M ^f   Chan, Clara C ^a,b  

^a CINCINNATI EYE INSTITUTE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d Bakersfield Eye Institute   (United States)

^e UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f Horizon Eye Care   (United States)

Author keywords

Limbal stem cell transplant; ocular surface disease; systemic immunosuppression

Indexed keywords

ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; COTRIMOXAZOLE; CREATININE; DAPSONE; FLUCONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VALGANCICLOVIR;

ADOLESCENT; ADULT; AGED; ANIRIDIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATOPIC KERATOCONJUNCTIVITIS; AVASCULAR NECROSIS; CEREBROVASCULAR ACCIDENT; CHILD; COMORBIDITY; CONGESTIVE HEART FAILURE; CYTOMEGALOVIRUS INFECTION; DEMOGRAPHY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECTODERMAL DYSPLASIA; EYE INJURY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HEART INFARCTION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KERATITIS; LIVER FUNCTION TEST; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MUCOUS MEMBRANE PEMPHIGOID; MYCOSIS; OCULAR SURFACE STEM CELL TRANSPLANTATION; PARESTHESIA; PENETRATING KERATOPLASTY; PNEUMOCYSTOSIS; PNEUMONIA; PRIORITY JOURNAL; RECURRENT INFECTION; RETROSPECTIVE STUDY; ROSACEA; SCHOOL CHILD; SIDE EFFECT; STEM CELL TRANSPLANTATION; STEVENS JOHNSON SYNDROME; THERMAL INJURY; TREATMENT DURATION; TREMOR; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CORNEAL DISEASES; DRUG THERAPY, COMBINATION; EPITHELIUM, CORNEAL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIMBUS CORNEAE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TACROLIMUS; TIME FACTORS; YOUNG ADULT;

EID: 84861098225     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31823f8b0c     Document Type: Article

References (26)

1. Holland EJ. Epithelial transplantation for the management of severe ocular surface disease. Trans Am Ophthalmol Soc. 1996;94:677-743.
2. Djalilian AR, Bagheri MM, Schwartz GS, et al. Keratolimbal allograft for the treatment of limbal stem cell deficiency. Presented at: the Scientific Program at Castroviejo Cornea Society; October 23, 1999; Orlando, FL.
3. Holland EJ, Schwartz GS. Changing concepts in the management of severe ocular surface disease over twenty-five years. Cornea. 2000;19:688-698.
4. Holland EJ, Schwartz GS. The Paton lecture: ocular surface transplantation: 10 years' experience. Cornea. 2004;23:425-431.
5. Djalilian AR, Nussenblatt RB, Holland EJ. Immunosuppressive therapy in ocular surface transplantation. In: Holland EJ, Mannis MJ, eds. Ocular Surface Disease: Medical and Surgical Management. New York, NY: Springer-Verlag; 2002:243-252.
6. Kim JY, Djalilian AR, Schwartz GS, et al. Ocular surface reconstruction: limbal stem cell transplantation. Ophthalmol Clin North Am. 2003;16:67-77.
7. Niederkorn JY. Effect of cytokine-induced migration of Langerhans cells on cornea allograft survival. Eye (Lond). 1995;9(pt 2):215-218.
8. Holland EJ, Gomes JA, Schwartz GS. Preoperative staging of disease severity. In: Holland EJ, Mannis MJ, eds. Ocular Surface Disease: Medical and Surgical Management. New York, NY: Springer-Verlag; 2002:158-167.
9. Salisbury JD, Gebhardt BM. Blood group antigens on human corneal cells demonstrated by immunoperoxidase staining. Am J Ophthalmol. 1981;91:46-50.
10. Tresler PA, Foulks GN, Sanfilippo F. The expression of HLA antigens in the human cornea. Am J Ophthalmol. 1984;98:763-772.
11. Chapman TM, Keating GM. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63:2803-2835.
12. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562-2575.
13. Woodle ES. Corticosteroid elimination in renal transplantation: pro. Transplant Proc. 2000;34:1693.
14. Alloway RR, Hanaway MJ, Trofe J, et al. A prospective, pilot study of early corticosteroid cessation in high-immunologic-risk patients: the Cincinnati experience. Transplant Proc. 2005;37:802-803.
15. Mycophenolate mofetil in rental transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. Transplantation. 1999;68:370-374.
16. Vanrenterghem YF. Which calcineurin inhibitor is preferred in renal transplantation: tacrolimus or cyclosporine? Curr Opin Nephrol Hypertens. 1999;8:669-674.
17. Boratynska M, Banasik M, Patrzalek D, et al. Conversion from cyclosporinebased immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection. Ann Transplant. 2006;11(2):51-56.
18. Tabbara KF. Pharmacologic strategies in the prevention and treatment of corneal transplant rejection. Int Ophthalmol. 2008;28:223-232.
19. Liang L, Sheha H, Tseng SC. Long-term outcomes of keratolimbal allograft for total limbal stem cell deficiency using combined immunosuppressive agents and correction of ocular surface deficits. Arch Ophthalmol. 2009;127:1428-1434.
20. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology. 2001;108:1838-1844.
21. Miri A, Al-Deiri B, Dua HS. Long-term outcomes of autolimbal and allolimbal transplants. Ophthalmology. 2010;117:1207-1213.
22. Ilari L, Daya SM. Long-term outcomes of keratolimbal allograft for the treatment of severe ocular surface disorders. Ophthalmology. 2002;109:1278-1284.
23. Solomon A, Ellies P, Anderson DF, et al. Long-term outcomes of keratolimbal allograft with or without penetrating keratoplasty for total limbal stem cell deficiency. Ophthalmology. 2002;109:1159-1166.
24. Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149:423-432.
25. Teoh SC, Hogan AC, Dick AD, et al. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol. 2008;146:752-760.
26. Mogilishetty G, Haird D, Alloway RR, et al. Comparison of immunosuppression related toxicities and complications in ocular surface transplant and renal transplant recipients: Implications for composite tissue transplantation [abstract]. Transplantation. 2008;86:11.